This is of some interest to MNTA investors insofar as MNTA may be working on an Orencia FoB for the US market.
FDA approval of the subcutaneous formulation of Orencia (#msg-65720598) occurred too late to have a material effect on the 3Q11 results.
All told, Orencia is doing pretty well for a drug that has been dismissed by many analysts as an also-ran. It is the clear leader in RA among non-TNFa biologics, easily outselling Rituxan and Actemra.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.